-
Lipid Nanoparticle Trafficking and Endosomal Escape
2026-08-19
A 2025 International Journal of Pharmaceutics study shows that high endolysosomal activity can increase lipid nanoparticle uptake while trapping particles in peripheral endosomes, reducing delivery to productive perinuclear compartments. The findings reposition intracellular trafficking balance—not uptake alone—as a central determinant of cytosolic release and transgene expression.
-
Diuron: Mechanism, Toxicology, and Research Use
2026-08-19
Diuron, also called 3-(3,4-dichlorophenyl)-1,1-dimethylurea, is a phenylurea photosynthesis inhibitor and herbicide research chemical. A 2025 study linked Diuron exposure to acute kidney injury in experimental models through JAK2/STAT1 signaling, while product specifications define its formulation, solvent compatibility, and storage requirements.
-
EZ Cap™ Cas9 mRNA for Causal Neurobiology
2026-08-18
Discover how Cas9 mRNA can convert Fyn–Stat3 observations into causal gene editing experiments. This guide combines Cap1 and 5-moUTP design with zebrafish neurodegeneration assay strategy, controls, and translational limitations.
-
Cy3-dCTP for Smarter DNA Labeling Decisions
2026-08-18
Cy3-dCTP enables direct fluorescent labeling of DNA and cDNA while preserving a rational path from polymerase choice to assay readout. This guide connects Cyanine 3-deoxycytidine triphosphate workflows with new evidence on ordered DNA interfaces, highlighting practical decisions, limitations, and quality controls.
-
Diuron: From PSII Assay to Renal Toxicology
2026-08-17
Diuron is more than a benchmark photosynthesis inhibitor: it is a useful probe for connecting plant electron-transport biology with emerging renal toxicology evidence. This article presents an assay-selection framework grounded in the 2025 JAK2/STAT1 study and practical product-handling considerations.
-
ATP and Mitochondrial Proteostasis: Assay Strategy
2026-08-17
Adenosine Triphosphate (ATP) is more than an energy currency: it is a context-dependent readout of mitochondrial metabolic control. This guide connects ATP measurements with the 2025 discovery that TCAIM regulates OGDH through mitochondrial proteostasis and translates the finding into better assay decisions.
-
Mitocytosis Targeting Boosts Mitochondrial Therapy
2026-08-16
Deng et al. identify mitocytosis as a resistance mechanism that weakens mitochondria-targeted antimetastatic therapy in migrasome-rich breast tumor models. Their hybrid-membrane nanoplatform combines mitochondrial damage with integrin-mediated mitocytosis inhibition, providing a strategy for improving organelle-directed treatment in aggressive tumors.
-
14-3-3 Signaling in ATG9A and PTOV1 Cancer Biology
2026-08-15
The reference study identifies ATG9A and PTOV1 as previously unrecognized 14-3-3-interacting proteins and defines distinct mechanisms linking them to autophagy and oncogenic signaling. Its combination of proximity labeling, quantitative proteomics, biochemical validation, and perturbation experiments provides a useful framework for studying context-dependent protein interactions in cancer biology.
-
2'3'-cGAMP: Endothelial STING Assay Workflows
2026-08-14
Translate direct STING activation into measurable endothelial, interferon, and tumor-microenvironment phenotypes with a controlled 2'3'-cGAMP workflow. This guide emphasizes cell-specific controls, water-based preparation, pathway-proximal readouts, and troubleshooting for immunotherapy research.
-
Cyclo (-RGDfC): From Integrin Biology to Translation
2026-08-14
A translational framework for using Cyclo (-RGDfC) and c(RGDfC) to connect αvβ3 integrin biology with tumor targeting, angiogenesis research, and more rigorous osteosarcoma model design.
-
AAPH Oxidative Stress and Lipid Peroxidation
2026-08-13
AAPH, also called 2,2'-Azobis(2-methylpropionamidine) dihydrochloride, is a water-soluble reactive oxygen species generator for controlled oxidative damage studies. Its thermal radical chemistry supports erythrocyte hemolysis, lipid peroxidation, and antioxidant evaluation, but AAPH exposure alone does not establish ferroptosis or implicate a selective molecular target.
-
EPZ5676: DOT1L Inhibitor Workflows
2026-08-13
EPZ5676 combines subnanomolar DOT1L potency with exceptional methyltransferase selectivity, making it useful for connecting biochemical inhibition to H3K79 methylation and leukemia-cell phenotypes. This guide presents practical assay workflows, controls, optimization strategies, and a careful way to adapt insights from cancer-stem-cell research without overextending the evidence.
-
Gly-Gly-Phe-Gly: Practical Linker Workflows
2026-08-12
Gly-Gly-Phe-Gly is a compact, sequence-defined spacer for antibody, peptide, and biomaterial conjugation. This guide shows how to build reproducible GGFG peptide workflows while separating linker performance from payload biology and disease-model readouts.
-
RSL3 Workflow for GPX4-Driven Ferroptosis
2026-08-12
Build a mechanism-resolved ferroptosis workflow with RSL3, from DMSO handling and dose–response design to lipid ROS, viability, and rescue controls. The approach also helps distinguish GPX4-dependent ferroptosis from apoptosis triggered by loss of RNA polymerase II.
-
TMEM16F, Ferroptosis, and Tumor Immune Rejection
2026-08-11
Yang et al. identify TMEM16F-mediated phospholipid scrambling as a late-stage suppressor of ferroptotic plasma membrane damage. The study shows that blocking this membrane-remodeling process enhances lytic death, slows tumor progression, and cooperates with PD-1 blockade to promote tumor immune rejection.